Merck Acquires Terns Pharma for $6.7 Billion to Bolster Oncology Pipeline

Merck & Co. has reached a definitive agreement to acquire biotech firm Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, or $53.00 per share in cash. This strategic move is designed to significantly expand Merck's oncology portfolio as it prepares for the upcoming "patent cliff" for its blockbuster cancer therapy, Keytruda. Keytruda is currently the company's top-selling product, and the loss of patent protection poses a substantial threat to long-term revenue. By integrating Terns Pharma's assets, Merck aims to secure its market leadership in the high-growth cancer treatment sector. However, market analysts suggest the acquisition may face interest from rival bidders, potentially driving the price higher. Analysts view the deal as a bullish development for TERN shareholders due to the acquisition premium, while MRK focuses on long-term sustainability.

Sources:reuters.comwsj.comglobenewswire.combusinesswire.cominvesting.commorningstar.compharmaphorum.comtipranks.comcnbc.commarketwatch.commarketwatch.commerck.comproactiveinvestors.combenzinga.com